Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $89

Benzinga Newsdesk www.benzinga.com Negative 56.5%

Neg 56.5% Neu 0% Pos 0%

Guggenheim analyst Brad Canino maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $106 to $89.